Allan R N, Thistle J L, Hofmann A F, Carter J A, Yu P Y
Gut. 1976 Jun;17(6):405-12. doi: 10.1136/gut.17.6.405.
Serum levels of total sulphated and total unsulphated lithocholates were each measured by a specific radioimmunoassay in 66 patients ingesting chenodeoxycholic (chenic) acid for gallstone dissoultion and in 35 gallstone patients ingesting either cholic acid or placebo. No changes occurred in serum lithocholate levels in the control groups. In patients ingesting chenic acid, there was a twofold increase in serum levels of total lithocholate, but the percent sulphation (greater than 75%) remained unchanged during chenotherapy. There was no correlation in the chenic acid treated group between serum lithocholate levels and the proportion of lithocholate in biliary bile acids or changes in serum SGOT. The data suggest that there is effective sulphation of lithocholate in such patients; this may explain the lack of hepatotoxicity observed during ingestion of chenic acid.
采用特定放射免疫分析法,分别测定了66例服用鹅去氧胆酸(鹅胆酸)以溶解胆结石的患者以及35例服用胆酸或安慰剂的胆结石患者血清中总硫酸化石胆酸和总非硫酸化石胆酸的水平。对照组患者血清石胆酸水平无变化。服用鹅胆酸的患者中,血清总石胆酸水平增加了两倍,但在鹅胆酸治疗期间,硫酸化百分比(大于75%)保持不变。在鹅胆酸治疗组中,血清石胆酸水平与胆汁中石胆酸比例或血清谷草转氨酶变化之间无相关性。数据表明,此类患者中石胆酸存在有效的硫酸化作用;这可能解释了服用鹅胆酸期间未观察到肝毒性的原因。